New Zealand considers Wegovy public funding

New Zealand's drug-funding agency, Pharmac, has added Semaglutide to its list of medicines suitable for future public funding. This decision has sparked debate about the drug's role in addressing New Zealand's high obesity rates. While Semaglutide, which uses Semaglutide, has shown significant weight loss effects in clinical trials, its current private cost of over NZD$400 per month makes it inaccessible to many. Public funding is seen as a way to improve equity, particularly for disproportionately affected communities like Māori and Pacific Islands Forum, and potentially reduce future healthcare costs. However, experts like Julie Trafford from Auckland University of Technology emphasize that pharmaceutical treatments alone are not a complete solution to the complex, systemic problem of obesity, advocating for broader environmental and social interventions.